LENZ Therapeutics, Inc. Debt-to-equity in % from Q1 2022 to Q3 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
LENZ Therapeutics, Inc. quarterly Debt-to-equity history and growth rate from Q1 2022 to Q3 2025.
  • LENZ Therapeutics, Inc. Debt-to-equity for the quarter ending September 30, 2025 was 6.05 %, a 45.7% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)

LENZ Therapeutics, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 6.05 -5.1 -45.7% Sep 30, 2025
Q2 2025 4.91 -43.5 -89.9% Jun 30, 2025
Q1 2025 4.84 +1.07K Mar 31, 2025
Q4 2024 6.02 +77.4 Dec 31, 2024
Q3 2024 11.2 +113 Sep 30, 2024
Q2 2024 48.4 -20.4 -29.7% Jun 30, 2024
Q1 2024 -1.07K -1.09K -6927% Mar 31, 2024
Q4 2023 -71.4 -79.1 -1024% Dec 31, 2023
Q3 2023 -102 -107 -2162% Sep 30, 2023
Q2 2023 68.8 +64.3 +1434% Jun 30, 2023
Q1 2023 15.7 +11.8 +304% Mar 31, 2023
Q4 2022 7.73 Dec 31, 2022
Q3 2022 4.93 Sep 30, 2022
Q2 2022 4.49 Jun 30, 2022
Q1 2022 3.88 Mar 31, 2022
* An asterisk sign (*) next to the value indicates that the value is likely invalid.